Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting

Marcello Rotta, Barry E. Storer, Firoozeh Sahebi, Judith A. Shizuru, Benedetto Bruno, Thoralf Lange, Edward D. Agura, Peter A. McSweeney, Michael A. Pulsipher, Parameswaran Hari, Richard Maziarz, Thomas R. Chauncey, Frederick R. Appelbaum, Mohamed L. Sorror, William Bensinger, Brenda M. Sandmaier, Rainer F. Storb, David G. Maloney

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Autologous hematopoietic cell transplantation (HCT) followed by nonmyeloablative allogeneic HCT (auto/alloHCT) provides cy-toreduction and graft-versus-myeloma effects. We report on long-term outcomes of 102 patients with multiple myeloma who received auto/alloHCT with a median follow-up of 6.3 years. Treatment consisted of high-dose melphalan and autograft followed by 2-Gy total body irradiation, with or without fludarabine, and alloHCT from human leukocyte antigen-identical siblings. Postgrafting immunosuppressive agent was cyclosporine or tacrolimus and mycopheno-late mofetil. Forty-two percent of patients developed grade 2 to 4 acute graft-versus-host disease (GVHD) and 74% extensive chronic GVHD. Five-year nonrelapse mortality after allografting was 18%, 95% related to GVHD or infections. Among 95 patients with detectable disease, 59 achieved complete remissions. Median time to progression was 5 years. Median overall survival (OS) was not reached. Median progression-free survival (PFS) was 3 years. Five-year OS and PFS were 64% and 36%, respectively. Seventy-three patients receiving autoHCT within 10 months from treatment initiation had 5-year OS of 69% and PFS of 37%. In multivariate analysis, β-2-microglobulin of more than 3.5 μg/mL at diagnosis and auto/ alloHCT more than 10 months after treatment initiation correlated with shorter OS (P = .03 and P = .02) and PFS (P = .04 and P = .03), whereas Karnofsky scores less than 90% at allotransplantation correlated with shorter PFS only (P = .005). Long-term disease control and GVHD remain key issues.

Original languageEnglish (US)
Pages (from-to)3383-3391
Number of pages9
JournalBlood
Volume113
Issue number14
DOIs
StatePublished - Apr 2 2009

Fingerprint

Cell Transplantation
Homologous Transplantation
Multiple Myeloma
Grafts
Disease-Free Survival
Graft vs Host Disease
Survival
Disease control
Melphalan
Whole-Body Irradiation
Autografts
Tacrolimus
Immunosuppressive Agents
HLA Antigens
Cyclosporine
Siblings
Therapeutics
Multivariate Analysis
Irradiation
Transplants

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Rotta, M., Storer, B. E., Sahebi, F., Shizuru, J. A., Bruno, B., Lange, T., ... Maloney, D. G. (2009). Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood, 113(14), 3383-3391. https://doi.org/10.1182/blood-2008-07-170746

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. / Rotta, Marcello; Storer, Barry E.; Sahebi, Firoozeh; Shizuru, Judith A.; Bruno, Benedetto; Lange, Thoralf; Agura, Edward D.; McSweeney, Peter A.; Pulsipher, Michael A.; Hari, Parameswaran; Maziarz, Richard; Chauncey, Thomas R.; Appelbaum, Frederick R.; Sorror, Mohamed L.; Bensinger, William; Sandmaier, Brenda M.; Storb, Rainer F.; Maloney, David G.

In: Blood, Vol. 113, No. 14, 02.04.2009, p. 3383-3391.

Research output: Contribution to journalArticle

Rotta, M, Storer, BE, Sahebi, F, Shizuru, JA, Bruno, B, Lange, T, Agura, ED, McSweeney, PA, Pulsipher, MA, Hari, P, Maziarz, R, Chauncey, TR, Appelbaum, FR, Sorror, ML, Bensinger, W, Sandmaier, BM, Storb, RF & Maloney, DG 2009, 'Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting', Blood, vol. 113, no. 14, pp. 3383-3391. https://doi.org/10.1182/blood-2008-07-170746
Rotta, Marcello ; Storer, Barry E. ; Sahebi, Firoozeh ; Shizuru, Judith A. ; Bruno, Benedetto ; Lange, Thoralf ; Agura, Edward D. ; McSweeney, Peter A. ; Pulsipher, Michael A. ; Hari, Parameswaran ; Maziarz, Richard ; Chauncey, Thomas R. ; Appelbaum, Frederick R. ; Sorror, Mohamed L. ; Bensinger, William ; Sandmaier, Brenda M. ; Storb, Rainer F. ; Maloney, David G. / Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. In: Blood. 2009 ; Vol. 113, No. 14. pp. 3383-3391.
@article{6ea3d5222cfb4d9e842607b68874affd,
title = "Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting",
abstract = "Autologous hematopoietic cell transplantation (HCT) followed by nonmyeloablative allogeneic HCT (auto/alloHCT) provides cy-toreduction and graft-versus-myeloma effects. We report on long-term outcomes of 102 patients with multiple myeloma who received auto/alloHCT with a median follow-up of 6.3 years. Treatment consisted of high-dose melphalan and autograft followed by 2-Gy total body irradiation, with or without fludarabine, and alloHCT from human leukocyte antigen-identical siblings. Postgrafting immunosuppressive agent was cyclosporine or tacrolimus and mycopheno-late mofetil. Forty-two percent of patients developed grade 2 to 4 acute graft-versus-host disease (GVHD) and 74{\%} extensive chronic GVHD. Five-year nonrelapse mortality after allografting was 18{\%}, 95{\%} related to GVHD or infections. Among 95 patients with detectable disease, 59 achieved complete remissions. Median time to progression was 5 years. Median overall survival (OS) was not reached. Median progression-free survival (PFS) was 3 years. Five-year OS and PFS were 64{\%} and 36{\%}, respectively. Seventy-three patients receiving autoHCT within 10 months from treatment initiation had 5-year OS of 69{\%} and PFS of 37{\%}. In multivariate analysis, β-2-microglobulin of more than 3.5 μg/mL at diagnosis and auto/ alloHCT more than 10 months after treatment initiation correlated with shorter OS (P = .03 and P = .02) and PFS (P = .04 and P = .03), whereas Karnofsky scores less than 90{\%} at allotransplantation correlated with shorter PFS only (P = .005). Long-term disease control and GVHD remain key issues.",
author = "Marcello Rotta and Storer, {Barry E.} and Firoozeh Sahebi and Shizuru, {Judith A.} and Benedetto Bruno and Thoralf Lange and Agura, {Edward D.} and McSweeney, {Peter A.} and Pulsipher, {Michael A.} and Parameswaran Hari and Richard Maziarz and Chauncey, {Thomas R.} and Appelbaum, {Frederick R.} and Sorror, {Mohamed L.} and William Bensinger and Sandmaier, {Brenda M.} and Storb, {Rainer F.} and Maloney, {David G.}",
year = "2009",
month = "4",
day = "2",
doi = "10.1182/blood-2008-07-170746",
language = "English (US)",
volume = "113",
pages = "3383--3391",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "14",

}

TY - JOUR

T1 - Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting

AU - Rotta, Marcello

AU - Storer, Barry E.

AU - Sahebi, Firoozeh

AU - Shizuru, Judith A.

AU - Bruno, Benedetto

AU - Lange, Thoralf

AU - Agura, Edward D.

AU - McSweeney, Peter A.

AU - Pulsipher, Michael A.

AU - Hari, Parameswaran

AU - Maziarz, Richard

AU - Chauncey, Thomas R.

AU - Appelbaum, Frederick R.

AU - Sorror, Mohamed L.

AU - Bensinger, William

AU - Sandmaier, Brenda M.

AU - Storb, Rainer F.

AU - Maloney, David G.

PY - 2009/4/2

Y1 - 2009/4/2

N2 - Autologous hematopoietic cell transplantation (HCT) followed by nonmyeloablative allogeneic HCT (auto/alloHCT) provides cy-toreduction and graft-versus-myeloma effects. We report on long-term outcomes of 102 patients with multiple myeloma who received auto/alloHCT with a median follow-up of 6.3 years. Treatment consisted of high-dose melphalan and autograft followed by 2-Gy total body irradiation, with or without fludarabine, and alloHCT from human leukocyte antigen-identical siblings. Postgrafting immunosuppressive agent was cyclosporine or tacrolimus and mycopheno-late mofetil. Forty-two percent of patients developed grade 2 to 4 acute graft-versus-host disease (GVHD) and 74% extensive chronic GVHD. Five-year nonrelapse mortality after allografting was 18%, 95% related to GVHD or infections. Among 95 patients with detectable disease, 59 achieved complete remissions. Median time to progression was 5 years. Median overall survival (OS) was not reached. Median progression-free survival (PFS) was 3 years. Five-year OS and PFS were 64% and 36%, respectively. Seventy-three patients receiving autoHCT within 10 months from treatment initiation had 5-year OS of 69% and PFS of 37%. In multivariate analysis, β-2-microglobulin of more than 3.5 μg/mL at diagnosis and auto/ alloHCT more than 10 months after treatment initiation correlated with shorter OS (P = .03 and P = .02) and PFS (P = .04 and P = .03), whereas Karnofsky scores less than 90% at allotransplantation correlated with shorter PFS only (P = .005). Long-term disease control and GVHD remain key issues.

AB - Autologous hematopoietic cell transplantation (HCT) followed by nonmyeloablative allogeneic HCT (auto/alloHCT) provides cy-toreduction and graft-versus-myeloma effects. We report on long-term outcomes of 102 patients with multiple myeloma who received auto/alloHCT with a median follow-up of 6.3 years. Treatment consisted of high-dose melphalan and autograft followed by 2-Gy total body irradiation, with or without fludarabine, and alloHCT from human leukocyte antigen-identical siblings. Postgrafting immunosuppressive agent was cyclosporine or tacrolimus and mycopheno-late mofetil. Forty-two percent of patients developed grade 2 to 4 acute graft-versus-host disease (GVHD) and 74% extensive chronic GVHD. Five-year nonrelapse mortality after allografting was 18%, 95% related to GVHD or infections. Among 95 patients with detectable disease, 59 achieved complete remissions. Median time to progression was 5 years. Median overall survival (OS) was not reached. Median progression-free survival (PFS) was 3 years. Five-year OS and PFS were 64% and 36%, respectively. Seventy-three patients receiving autoHCT within 10 months from treatment initiation had 5-year OS of 69% and PFS of 37%. In multivariate analysis, β-2-microglobulin of more than 3.5 μg/mL at diagnosis and auto/ alloHCT more than 10 months after treatment initiation correlated with shorter OS (P = .03 and P = .02) and PFS (P = .04 and P = .03), whereas Karnofsky scores less than 90% at allotransplantation correlated with shorter PFS only (P = .005). Long-term disease control and GVHD remain key issues.

UR - http://www.scopus.com/inward/record.url?scp=65149104407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65149104407&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-07-170746

DO - 10.1182/blood-2008-07-170746

M3 - Article

C2 - 19015394

AN - SCOPUS:65149104407

VL - 113

SP - 3383

EP - 3391

JO - Blood

JF - Blood

SN - 0006-4971

IS - 14

ER -